Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$401000.0.

  • Cytosorbents' Tax Provisions changed N/A to -$401000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 15706.34%. This contributed to the annual value of -$1.7 million for FY2024, which is 10778.47% down from last year.
  • Cytosorbents' Tax Provisions amounted to -$401000.0 in Q3 2025.
  • Over the past 5 years, Cytosorbents' Tax Provisions peaked at -$401000.0 during Q3 2025, and registered a low of -$1.7 million during Q4 2024.
  • In the last 5 years, Cytosorbents' Tax Provisions had a median value of -$813739.0 in 2023 and averaged -$946830.4.
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 3469.79% in 2021, then tumbled by 10778.47% in 2024.
  • Over the past 5 years, Cytosorbents' Tax Provisions (Quarter) stood at -$736003.0 in 2021, then tumbled by 48.45% to -$1.1 million in 2022, then increased by 25.52% to -$813739.0 in 2023, then tumbled by 107.78% to -$1.7 million in 2024, then soared by 76.28% to -$401000.0 in 2025.
  • Its Tax Provisions stands at -$401000.0 for Q3 2025, versus -$1.7 million for Q4 2024 and -$813739.0 for Q4 2023.